Trial Profile
A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jun 2019
Price :
$35
*
At a glance
- Drugs Nolasiban (Primary)
- Indications Preterm labour
- Focus Proof of concept; Therapeutic Use
- Acronyms TERM
- Sponsors ObsEva
- 11 Jun 2019 This trial was completed in UK - MHRA (end date: 2016-10-28), according to European Clinical Trials Database.
- 17 Jan 2017 Status changed from active, no longer recruiting to discontinued due to Enrolment difficulties.
- 17 Jan 2017 Status changed from active, no longer recruiting to discontinued due to Enrolment difficulties.